Reaching toward a cure for sickle cell disease

The National Heart, Lung, and Blood Institute (NHLBI) has awarded Case Western Reserve University up to $3.7 million to assess emerging genome-editing based therapies being tested for curing sickle cell disease (SCD) at leading U.S research universities and hospitals.

SCD is the most well-known among a group of inherited blood disorders, affecting about 100,000 people in the United States and about 20 million worldwide, according to a 2018 National Institutes of Health (NIH) statement announcing the NHLBI Cure Sickle Cell Initiative.

While Promoting Diseases Like Cancer, These Enzymes Also Cannibalize Each Other

In diseases like cancer, atherosclerosis, and sickle cell anemia, cathepsins promote their propagation. Drug trials to inhibit these enzymes have failed due to baffling side effects. Now a new study examines cathepsins in systems to remove some of the bafflement.